CHICAGO, Sept 3 Celgene Corp (CELG.O) said it
plans to file a complaint alleging infringement against India's
Natco Pharma Ltd (NATP.BO), which has submitted a request to
the U.S. Food and Drug Administration for authorization to make
and sell generic versions of Celgene's cancer drug Revlimid in
the United States.
Celgene said it intends to vigorously enforce its
intellectual property rights for Revlimid, its most important
drug, and will file the complaint within the required 45-day
Natco's Abbreviated New Drug Application submitted to the
FDA requests authorization to make the drug in 5, 10, 15, and
25 milligram capsules.
Revlimid is currently protected by 12 issued patents listed
in the FDAs Approved Drug Products List and has additional
patent applications pending, Celgene said.
(Reporting by Debra Sherman, editing by Gerald E. McCormick)